How Lung Cancer Burden and Diagnostics Are Powering the Global NSCLC Market to USD 35.8 Billion by 2035

The global non-small cell lung cancer market was valued at $18.4 billion in 2024 and is projected to reach $35.8 billion by 2035, growing at a CAGR of 6.4% during the forecast period (2025–2035). The global non-small cell lung cancer (NSCLC) market is expanding steadily due to the rising incidence of lung cancer worldwide, driven by aging populations, smoking prevalence, and increasing exposure to environmental pollutants. Improved awareness and earlier detection are also contributing to higher diagnosis rates, strengthening demand for advanced treatment options.

Browse the full report description of “Non-Small Cell Lung Cancer Market Size, Share & Trends Analysis Report by Type (Adenocarcinomas, Squamous Cell Carcinoma, Large Cell Carcinomas, and Others) by Therapy (Chemotherapy, Targeted Therapy, Radiation Therapy, Surgery, Cryosurgery, and Others) by Diagnosis (CT Scan, X-Rays, Sputum Cytology, Bronchoscopy, Laboratory Tests, Thoracoscopy, and Others), and by End-User Industry (Multispeciality Hospitals, and Cancer Research Centers) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/non-small-cell-lung-cancer-market

Technological advancements in diagnostics and therapy—such as next-generation sequencing, liquid biopsies, targeted therapies, and immuno-oncology—are transforming NSCLC management. Alongside these innovations, supportive healthcare policies, increased oncology funding, and public–private investments are accelerating patient access to precision treatments and clinical trials.

Key Developments Influencing the NSCLC Market

• 2024: Health authorities across multiple regions expanded lung cancer screening initiatives using low-dose CT scans, leading to increased early-stage NSCLC detection.
• 2024: Advances in molecular diagnostics enabled broader adoption of companion diagnostics, supporting personalized treatment selection for NSCLC patients.
• 2025: Governments and private investors increased funding for oncology research and clinical trials, accelerating the development and approval of novel NSCLC therapies.

Focus on Precision Oncology and Access Expansion

Pharmaceutical and biotechnology companies are intensifying R&D efforts in biomarker-driven therapies and combination regimens to improve survival outcomes. Industry players are also collaborating with healthcare systems and governments to expand screening programs, improve reimbursement coverage, and strengthen oncology care infrastructure globally.

Recent Strategic Developments in the Global Non?Small Cell Lung Cancer (NSCLC) Market

• In 2025, AstraZeneca plc announced the global launch of its next?generation targeted therapy for NSCLC, featuring improved progression?free survival and a favorable safety profile, aimed at patients with specific genetic mutations.
• In 2024, Pfizer Inc. completed the acquisition of a biotech firm specializing in immuno?oncology, expanding its pipeline of NSCLC therapies including combination regimens that enhance immune response and treatment efficacy.
• In 2025, Merck & Co., Inc. entered a strategic collaboration with a leading academic cancer research institute to co?develop and clinically evaluate novel checkpoint inhibitor combinations for advanced NSCLC treatment.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Type
• Therapy
• Diagnosis
• End-User Industry

• Competitive Landscape – AstraZeneca PLC, Bristol-Myers Squibb, Hoffmann-La Roche Ltd., Pfizer Inc. and Merck & Co. Inc.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Non-Small Cell Lung Cancer Market Report Segment

By Type

• Adenocarcinomas
• Squamous Cell Carcinoma
• Large Cell Carcinomas
• Others

By Therapy

• Chemotherapy
• Targeted Therapy
• Radiation Therapy
• Surgery
• Cryosurgery
• Others

By Diagnosis

• CT Scan
• X-Rays
• Sputum Cytology
• Bronchoscopy
• Laboratory Tests
• Thoracoscopy
• Others

By End-User Industry

• Multispeciality Hospitals
• Cancer Research Centers

Global Non-Small Cell Lung Cancer Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/non-small-cell-lung-cancer-market